908 Devices Inc.MASS财报
Nasdaq · 医疗保健 · 测量与控制设备（未另分类）
908 Devices Inc.是一家专注于研发、生产高性能便携式质谱分析设备及相关解决方案的科技企业，产品覆盖生命科学研究、生物制药制造、公共安全、法医鉴定、工业过程监测等领域，服务全球科研机构、制药企业及政府部门客户。
主要股东
| 股东 | 持股比例 | 股数 | 变动 | 截至 |
|---|---|---|---|---|
| ARCH | 17.70% | 5.7M | — | 2024-02-09 |
| ARCH Venture Fund VII, L.P. | 16.40% | 5.7M | — | 2024-11-14 |
| ARK | 13.42% | 4.3M | — | 2024-01-29 |
| Ameriprise Financial, | 5.84% | 1.9M | — | 2024-02-14 |
| BlackRock, Inc. | 5.40% | 1.9M | 无变化 | 2024-11-08 |
| The Vanguard Group | 5.39% | 1.7M | — | 2024-02-13 |
| Eventide Asset Management, LLC | 4.42% | 1.4M | — | 2024-02-14 |
| Alger Associates, Inc. | 3.80% | 1.2M | — | 2023-11-13 |
| S.S. OR | 2.49% | 861.4K | ▼ -3.81pp | 2024-11-14 |
内部人交易
Net 90d: −$828.4K · buys $0 / sells $828.4K时间范围:
类型:
身份:
| 内部人 | 身份 | 类型 | ||||
|---|---|---|---|---|---|---|
| 2026-04-10 | McCallion Kevin J. | SVP, Products and Production | Option exercise | 2.7K | $1.05 | $2.8K |
| 2026-04-10 | McCallion Kevin J. | SVP, Products and Production | Sell (open market) | 2.7K | $7.01 | $18.9K |
| 2026-04-10 | Brown Christopher D. | Director | Sell (open market) | 17.6K | $7.07 | $124.3K |
| 2026-04-09 | McCallion Kevin J. | SVP, Products and Production | Option exercise | 5.4K | $1.05 | $5.7K |
| 2026-04-09 | McCallion Kevin J. | SVP, Products and Production | Sell (open market) | 5.4K | $7.03 | $38.1K |
| 2026-04-09 | Brown Christopher D. | Director | Sell (open market) | 7.4K | $7.04 | $52.0K |
| 2026-04-08 | McCallion Kevin J. | SVP, Products and Production | Option exercise | 18.6K | $1.05 | $19.5K |
| 2026-04-08 | McCallion Kevin J. | SVP, Products and Production | Sell (open market) | 18.6K | $7.05 | $131.0K |
| 2026-04-08 | Brown Christopher D. | Director | Sell (open market) | 15.0K | $7.05 | $106.0K |
| 2026-03-02 | McCallion Kevin J. | SVP, Products and Production | Option exercise | 7 | $1.05 | $7 |
1–10 of 25
第 1 页 / 共 3 页